Cypris Therapeutics utilizes proprietary synthetic chemistry and drug development expertise to create next-generation pharmaceutical therapies. The company focuses on developing treatments inspired by natural molecules to address urgent unmet clinical needs, particularly in aggressive cancers. Their technology aims to deliver life-saving therapies where current options are inadequate.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ILFounders
Product
Problem
Brain, colon, and pancreatic cancers lack effective treatments, leaving patients with limited options. Current therapies often fail to provide adequate relief or long-term solutions for these therapeutically resistant diseases.
Solution
Cypris Therapeutics employs proprietary synthetic chemistry techniques to develop novel therapies specifically targeting brain, colon, and pancreatic cancers. By drawing inspiration from molecules found in nature, the company's technology allows for iterative improvements, creating next-generation treatments. Through a collaboration with Ichor Life Sciences and Florida State University, Cypris aims to translate innovative chemical solutions into clinically viable options for patients facing these challenging diseases. The company's approach focuses on addressing unmet clinical needs by creating solutions where they are urgently needed.
Target Audience
The primary target audience includes patients diagnosed with brain, colon, and pancreatic cancers, as well as the oncologists and medical professionals who treat them.
Features
- Proprietary synthetic chemistry techniques for creating novel therapeutic molecules.
- Focus on brain, colon, and pancreatic cancers with limited treatment options.
- Therapies inspired by molecules found in nature, enhanced through synthetic chemistry.
- Collaboration with Ichor Life Sciences and Florida State University for translating research into clinical applications.